Three Complementary Approaches to Characterize Buprenorphine Misuse

References

• Arimone, Y., Bidault, I., Dutertre, J. P., Gérardin, M., Guy, C., Haramburu, F., & Théophile, H. (2013). Valnet-rabier MB; Cercle de Réflexion sur l'Imputabilité Updating the French method for the causality assessment of adverse drug reactions. Thérapie, 68, 69–76.
   Google Scholar
• Baumevieille, M., Miremont, G., Haramburu, F., Maurain, C., & Begaud, B. (2001). Le système français d’évaluation de la pharmacodépendance et de l'abus: Consécration juridique. Thérapie, 56, 15–22.
   Google Scholar
• Bégaud, B., Martin, K., Haramburu, F., & Moore, N. (2002). Rates of spontaneous reporting of adverse drug reactions in France. JAMA, 288, 1588.
   Google Scholar
• Békaert, J., & Podevin, G. (2014). Psychopathology of the misuse of Subutex®: The Popeye syndrome. Encephale. doi: 10.1016/j.encep.2014.08.009.
   Google Scholar
• Beynon, C. M. (2009). Drug use and ageing: Older people do take drugs! Age and Ageing, 38, 8–10.
   Google Scholar
• Boczek, C., Frauger, E., Micallef, J., Allaria-Lapierre, V., Reggio, P., & Sciotino, V. (2012). Taux de penetration des génériques de la buprénorphine haut dosage: Principales tendances de 2006 à 2008. Thérapie, 67, 129–136.
   Google Scholar
• Cazorla, C., Grenier de Cardenal, D., Schuhmacher, H., Thomas, L., Wack, A., May, T., & Rabaud, C. (2005). Infectious complications and misuse of high-dose buprenorphine. Presse Medicale, 34, 719–724.
   Google Scholar
• Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). Factors contributing to the rise of buprenorphine misuse: 2008–2013. Drug and Alcohol Dependence, 142, 98–104.
   Google Scholar
• Eiden, C., Ripault, M. P., Larrey, D., Faillie, J. L., Pinzani, V., Pageaux, G. P., & Peyrière, H. (2013). Acute hepatitis and renal failure related to intranasal buprenorphine misuse: Case report and analysis of cases reported to the French network for drug monitoring. Annals of Pharmacotherapy, 47, 1721–1726.
   Google Scholar
• El-Haïk, Y., Frauger, E., Tanti-Hardouin, N., Micallef, J., & Thirion, X. (2014). Use of generic high dose buprenorphine (HDB): About a qualitative survey. Thérapie, 69, 239–241.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. (2008). Substance use among older adults: A neglected problem Lisbon, Portugal: Author.
   Google Scholar
• Fatseas, M., & Auriacombe, M. (2007). Why buprenorphine is so successful in treating opiate addiction in France. Current Psychiatry Reports, 9, 358–364.
   Google Scholar
• Frauger, E., Moracchini, C., Le Boisselier, R., Braunstein, D., Thirion, X., Micallef, J., & French CEIPA-A Network. (2013). OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundamental & Clinical Pharmacology, 27, 672–682.
   Google Scholar
• Frauger, E., Nordmann, S., Orleans, V., Pradel, V., Pauly, V., Thirion, X., & réseau des CEIPs. (2012). Which psychoactive prescription drugs are illegally obtained and through which way of acquisition? About OPPIDUM survey. Fundamental & Clinical Pharmacology, 26, 549–556.
   Google Scholar
• Grau, D., Vidal, N., Faucherre, V., Leglise, Y., Pinzani, V., Blayac, J. P., & Peyriere, H. (2010). Complications infectieuses induites par le mésusage de la buprénorphine haut dosage (Subutex®): Analyse rétrospective de 42 observations. Review Medical International, 31, 188–193.
   Google Scholar
• Ho, R. C., Ho, E. C., & Mak, A. (2009). Cutaneous complications among i.v. buprenorphine users. Journal of Dermatology, 36, 22–29.
   Google Scholar
• Horyniak, D., Dietze, P., Larance, B., Winstock, A., & Degenhardt, L. (2011). The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. International Journal of Drug Policy, 22, 167–171.
   Google Scholar
• INSEE. (n.d.). Chiffre du chômage Languedoc-Roussillon INSEE. Unemployment database. Retrieved from http://www.insee.fr/fr/themes/document.asp?reg_id=32&ref_id=23950
   Google Scholar
• Jouanjus, E., Pourcel, L., Saivin, S., Molinier, L., & Lapeyre-Mestre, M. (2012). Use of multiple sources and capture-recapture method to estimate the frequency of hospitalizations related to drug abuse. Pharmacoepidemiology and Drug Safety, 21, 733–741.
   Google Scholar
• Lapeyre-Mestre, M., Llau, M. E., Gony, M., Navel, A. M., Bez, J., Grau, M., & Montastruc, J. L. (2003). Opiate maintenance with buprenorphine in ambulatory care: A 24-week follow-up study of new users. Drug and Alcohol Dependence, 72, 297–303.
   Google Scholar
• Larance, B., Degenhardt, L., Lintzeris, N., Winstock, A., & Mattick, R. (2011). Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug and Alcohol Review, 30, 236–245.
   Google Scholar
• Lavonas, E. J., Severtson, S. G., Martinez, E. M., Bucher-Bartelson, B., Le Lait, M. C., Green, J. L., & Dart, R. C. (2014). Abuse and diversion of buprenorphine sublingual tablets and film. Journal of Substance Abuse Treatment, 47, 27–34.
   Google Scholar
• Lofwall, M. R., Martin, J., Tierney, M., Fatséas, M., Auriacombe, M., & Lintzeris, N. (2014). Buprenorphine diversion and misuse in outpatient practice. Journal of Addiction Medicine, 8, 327–332.
   Google Scholar
• Micallef, J., Jolliet, P., Victorri-Vigneau, C., Mallaret, M., Richard, N., Haramburu, F., & Lapeyre-Mestre, M. (2008). Assessment of the abuse and pharmacodependence potential during drug development. Therapie, 63, 55–65.
   Google Scholar
• Nordmann, S., Frauger, E., Pauly, V., Orléans, V., Pradel, V., Mallaret, M., & Micallef, J. (2012). Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey. Pharmacoepidemiology and Drug Safety, 21, 184–190.
   Google Scholar
• Pauly, V., Frauger, E., Pradel, V., Rouby, F., Berbis, J., Natali, F., … Thirion, X. (2011). Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling high dosage buprenorphine abuse. Drug and Alcohol Dependence, 113, 29–36.
   Google Scholar
• Peyrière, H., Eiden, C., Micallef, J., Lapeyre-Mestre, M., Faillie, J. L., & Blayac, J. P. (2013). Slow-release oral morphine sulfate abuse: Results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France. European Addiction Research, 19, 235–244.
   Google Scholar
• Peyrière, H., Tatem, L., Bories, C., Pageaux, G. P., Blayac, J. P., & Larrey, D. (2009). Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: Report of two cases of disappearance of viral replication after acute hepatitis. Annals of Pharmacotherapy, 43, 973–977.
   Google Scholar
• Roux, P., Villes, V., Blanche, J., Bry, D., Spire, B., Feroni, I., & Carrieri, M. P. (2008). Buprenorphine in primary care: Risk factors for treatment injection and implications for clinical management. Drug and Alcohol Dependence, 97, 105–113.
   Google Scholar
• Thirion, X., Micallef, J., Barrau, K., Djezzar, S., Sanmarco, J. L., & Lagier, G. (2001). Observation of psychoactive substance consumption: Methods and results of the French OPPIDUM programme. European Addiction Research, 7, 32–36.
   Google Scholar
• Uosukainen, H. L., Kauhanen, J., Bell, J. S., Ronkainen, K., Tiihonen, J., Föhr, J., & Korhonen, M. J. (2013). Mortality among clients seeking treatment for buprenorphine abuse in Finland. Drug and Alcohol Dependence, 133, 391–397.
   Google Scholar
• Vidal-Trecan, G., Varescon, I., Nabet, N., & Boissonnas, A. (2003). Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug and Alcohol Dependence, 69, 175–181.
   Google Scholar
• Wilquin, M., & Robinet, S. (2012). Analyse de la répartition par départements des patients recevant un traitement par BHD (Subutex® et ses génériques) et par méthadone en 2011. Le Flyer, 46, 4–15.
   Google Scholar
• Winstock, A. R. (2008). Buprenorphine use by the smoking route in goals in NSW. Drug and Alcohol Review, 27, 449–450.
   Google Scholar
• World Health Organization. (2006). Lexicon of alcohol and drug terms. Retrieved from http://www.who.int/substance_abuse/terminology/who_lexicon/en/
   Google Scholar
• Yokell, M., Zaller, N., Green, T., & Rich, J. (2011). Buprenorphine and buprenorphine/Naloxone diversion, misuse and illicit use: An international review. Current Drug Abuse Review, 4, 28–41.
   Google Scholar